Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
24.1.2025 06:30:00 CET | ACCESS Newswire | Press release
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats
CAMBRIDGE, MA / ACCESS Newswire / January 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years.
"This agreement presents an opportunity for Moderna to support and strengthen national COVID-19 vaccination campaigns across participating countries," said Chantal Friebertshäuser, Senior Vice President, General Manager - Europe & Middle-East, Moderna. "Diversity of supply and availability of vaccine formats such as pre-filled syringes are vital to help increase vaccination rates and enhance vaccination campaign efficiency, ultimately strengthening health security."
Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease the risk of administration errors and save time, which may ultimately improve vaccination campaign efficiency.
In September 2024, the European Commission (EC) granted marketing authorization for an updated formulation of Moderna's COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna securing an agreement in the European Union for the supply of its mRNA COVID-19 vaccine; the opportunity and potential for up to 17 participating countries to order COVID-19 vaccines from Moderna over a four-year period; and healthcare provider preferences for prefilled syringes. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Luke Mircea-Willats
Sr. Director, International Communications
Luke.mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
ModernaTX, Inc

Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release
BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.
Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release
CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security
International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release
PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning
OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an
Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release
MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom